Home / About Barrow Neurological Institute / News & Articles / In the News / Barrow Neurologist Discusses Alzheimer’s Drug Trial Results
Barrow Neurologist Discusses Alzheimer’s Drug Trial Results
- Byline: Barrow Media Relations
- December 2, 2022
A study published in the New England Journal of Medicine found that an experimental Alzheimer’s drug, known as lecanemab, moderately slowed the progression of the disease. However, the researchers say longer clinical trials are needed to evaluate the safety of this amyloid-targeting drug.
Marwan Sabbagh, MD, a neurologist in the Alzheimer’s and Memory Disorders Program at Barrow Neurological Institute and a co-author on the study, discussed these safety concerns at the 15th Clinical Trials on Alzheimer’s Disease conference in San Francisco, California. He has been quoted by several news outlets.
- Nature: Heralded Alzheimer’s drug works — but safety concerns loom
- The Washington Post: Alzheimer’s drug shows promise but needs more study for safety, researchers say
- CNN: Experimental drug appears to slow progression of Alzheimer’s disease in clinical trial but raises safety concerns
- ABC News: New data shows Alzheimer’s drug can slow cognitive decline
- MedPage Today: Alzheimer’s drug slows decline, trial data show
- NPR: Study: Alzheimer’s drug shows modest success in slowing declines in memory, thinking
- Neurology Live: Working Towards Lowering ARIA Rates, Reducing Amyloid Plaques: Marwan Sabbagh, MD, FAAN